MA34806B1 - Compositions pharmaceutiques - Google Patents
Compositions pharmaceutiquesInfo
- Publication number
- MA34806B1 MA34806B1 MA35945A MA35945A MA34806B1 MA 34806 B1 MA34806 B1 MA 34806B1 MA 35945 A MA35945 A MA 35945A MA 35945 A MA35945 A MA 35945A MA 34806 B1 MA34806 B1 MA 34806B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- quinolin
- methyl
- formula
- therapeutic compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique pour l'administration orale d'un composé thérapeutique de formule (I), qui comprend les éléments suivants : des granules comportant au moins un composé thérapeutique de formule (I) (voir ci-dessous), en particulier 2-méthyl-2-[4-(3-méthyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phényl]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41953810P | 2010-12-03 | 2010-12-03 | |
US201161436324P | 2011-01-26 | 2011-01-26 | |
PCT/US2011/062837 WO2012075253A2 (fr) | 2010-12-03 | 2011-12-01 | Compositions pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34806B1 true MA34806B1 (fr) | 2014-01-02 |
Family
ID=45346568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35945A MA34806B1 (fr) | 2010-12-03 | 2011-12-01 | Compositions pharmaceutiques |
Country Status (21)
Country | Link |
---|---|
US (1) | US20130245061A1 (fr) |
EP (1) | EP2645999A2 (fr) |
JP (1) | JP2013544845A (fr) |
KR (1) | KR20140010009A (fr) |
CN (1) | CN103237544A (fr) |
AR (1) | AR084067A1 (fr) |
AU (1) | AU2011336478A1 (fr) |
CA (1) | CA2817618A1 (fr) |
CL (1) | CL2013001557A1 (fr) |
CO (1) | CO6801722A2 (fr) |
EC (1) | ECSP13012654A (fr) |
GT (1) | GT201300144A (fr) |
MA (1) | MA34806B1 (fr) |
MX (1) | MX2013006187A (fr) |
NZ (1) | NZ610467A (fr) |
PE (1) | PE20140792A1 (fr) |
RU (1) | RU2013130224A (fr) |
SG (1) | SG190210A1 (fr) |
TW (1) | TW201304779A (fr) |
WO (1) | WO2012075253A2 (fr) |
ZA (1) | ZA201303223B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013192367A1 (fr) * | 2012-06-22 | 2013-12-27 | Novartis Ag | Traitement d'une tumeur neuroendocrine |
WO2014048782A1 (fr) * | 2012-09-27 | 2014-04-03 | Basf Se | Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile |
EP3277681B1 (fr) | 2015-04-02 | 2019-05-08 | Merck Patent GmbH | Imidazolonylquinoléines et leur utilisation comme inhibiteurs des kinases atm |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
KR20190089005A (ko) | 2016-11-23 | 2019-07-29 | 노파르티스 아게 | 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법 |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
WO2021026421A1 (fr) * | 2019-08-07 | 2021-02-11 | Aclipse One Inc. | Compositions pharmaceutiques de (6as)-6-méthyl -5,6,6a,7-tétrahydro-4 h-dibenzo[de,g]quinoléine-10,11-diol |
FI4076404T3 (fi) * | 2019-12-20 | 2024-01-31 | Intervet Int Bv | Farmaseuttinen pyratsolikoostumus |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
EP1687305B1 (fr) * | 2003-11-21 | 2008-07-09 | Novartis AG | Derives d'1h-imidazoquinoline en tant qu'inhibiteurs de la proteine kinase |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20080125477A1 (en) * | 2006-05-16 | 2008-05-29 | Decode Genetics, Ehf. | 7-(acryloyl) indole compositions and methods of making and using same |
PE20080766A1 (es) * | 2006-08-30 | 2008-06-15 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
US20100016449A1 (en) * | 2006-12-21 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Formulations with Improved Bioavailability |
EP2129379B1 (fr) * | 2007-02-20 | 2019-04-10 | Novartis AG | Imidazoquinoléines comme inhibiteurs doubles de kinase lipidique et de mtor |
-
2011
- 2011-12-01 CA CA2817618A patent/CA2817618A1/fr not_active Abandoned
- 2011-12-01 EP EP11794907.3A patent/EP2645999A2/fr not_active Withdrawn
- 2011-12-01 JP JP2013542171A patent/JP2013544845A/ja active Pending
- 2011-12-01 US US13/989,250 patent/US20130245061A1/en not_active Abandoned
- 2011-12-01 MX MX2013006187A patent/MX2013006187A/es not_active Application Discontinuation
- 2011-12-01 AU AU2011336478A patent/AU2011336478A1/en not_active Abandoned
- 2011-12-01 CN CN2011800576307A patent/CN103237544A/zh active Pending
- 2011-12-01 MA MA35945A patent/MA34806B1/fr unknown
- 2011-12-01 PE PE2013001327A patent/PE20140792A1/es not_active Application Discontinuation
- 2011-12-01 WO PCT/US2011/062837 patent/WO2012075253A2/fr active Application Filing
- 2011-12-01 SG SG2013035480A patent/SG190210A1/en unknown
- 2011-12-01 RU RU2013130224/15A patent/RU2013130224A/ru not_active Application Discontinuation
- 2011-12-01 AR ARP110104478A patent/AR084067A1/es unknown
- 2011-12-01 KR KR1020137017289A patent/KR20140010009A/ko not_active Application Discontinuation
- 2011-12-01 NZ NZ610467A patent/NZ610467A/en not_active IP Right Cessation
- 2011-12-02 TW TW100144445A patent/TW201304779A/zh unknown
-
2013
- 2013-05-03 ZA ZA2013/03223A patent/ZA201303223B/en unknown
- 2013-05-30 CO CO13133022A patent/CO6801722A2/es not_active Application Discontinuation
- 2013-05-31 CL CL2013001557A patent/CL2013001557A1/es unknown
- 2013-06-03 GT GT201300144A patent/GT201300144A/es unknown
- 2013-06-03 EC ECSP13012654 patent/ECSP13012654A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO6801722A2 (es) | 2013-11-29 |
EP2645999A2 (fr) | 2013-10-09 |
KR20140010009A (ko) | 2014-01-23 |
US20130245061A1 (en) | 2013-09-19 |
WO2012075253A2 (fr) | 2012-06-07 |
CA2817618A1 (fr) | 2012-06-07 |
ECSP13012654A (es) | 2013-08-30 |
AU2011336478A1 (en) | 2013-06-06 |
AR084067A1 (es) | 2013-04-17 |
MX2013006187A (es) | 2013-07-15 |
ZA201303223B (en) | 2014-01-29 |
RU2013130224A (ru) | 2015-01-10 |
CN103237544A (zh) | 2013-08-07 |
CL2013001557A1 (es) | 2013-10-25 |
JP2013544845A (ja) | 2013-12-19 |
TW201304779A (zh) | 2013-02-01 |
NZ610467A (en) | 2015-01-30 |
SG190210A1 (en) | 2013-06-28 |
WO2012075253A3 (fr) | 2012-08-09 |
PE20140792A1 (es) | 2014-07-09 |
GT201300144A (es) | 2014-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34806B1 (fr) | Compositions pharmaceutiques | |
UA99132C2 (ru) | Производные дикарбоновых кислот как агонисты рецепторов s1p1 | |
WO2008007211A8 (fr) | Composés de carboxyamide bicycliques à n-bicycloalkyle substitué | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MX2013001805A (es) | Derivados de 2-(arilamino)-3h-imidazo [4,5-b] piridina-6-carboxamida y su uso como inhibidores de mpges-1. | |
EA018193B3 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
UA106199C2 (ru) | Производные аминобензамида как агенты, пригодные для использования для борьбы с паразитами животных | |
MA32904B1 (fr) | Composes de purine | |
MY151295A (en) | Pyrimidyl indoline compound | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
MX2012001660A (es) | Formulaciones que contienen linaclotida para adminstracion oral. | |
WO2011006935A3 (fr) | Dérivés de tétrazole | |
MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. | |
WO2012128582A3 (fr) | Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant | |
UA84896C2 (ru) | Производные гидронопола как агонисты человеческих рецепторов orl1 | |
MA32406B1 (fr) | Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens | |
SE0303480D0 (sv) | Benzofuranes | |
PT1981862E (pt) | Compostos relacionados com lantionina para o tratamento de doenças inflamatórias | |
WO2009034432A8 (fr) | Nouveaux composés actifs utilisés comme antagonistes des récepteurs muscariniques | |
DE602007005387D1 (de) | Ptors | |
MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments | |
JO2820B1 (en) | Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases |